Metformin improves the angiogenic potential of human CD34⁺ cells co-incident with downregulating CXCL10 and TIMP1 gene expression and increasing VEGFA under hyperglycemia and hypoxia within a therapeutic window for myocardial infarction. [electronic resource]
Producer: 20161011Description: 27 p. digitalISSN:- 1475-2840
- Angiogenesis Inducing Agents -- pharmacology
- Antigens, CD34 -- metabolism
- Biomarkers -- metabolism
- Cell Hypoxia
- Cells, Cultured
- Chemokine CXCL10 -- genetics
- Dose-Response Relationship, Drug
- Down-Regulation
- Gene Expression Profiling
- Human Umbilical Vein Endothelial Cells -- drug effects
- Humans
- Hyperglycemia -- drug therapy
- Hypoglycemic Agents -- pharmacology
- Membrane Proteins -- genetics
- Metformin -- pharmacology
- Myocardial Infarction -- drug therapy
- Neovascularization, Physiologic -- drug effects
- Oxidoreductases -- genetics
- Phenotype
- Stem Cells -- drug effects
- Tissue Inhibitor of Metalloproteinase-1 -- genetics
- Up-Regulation
- Vascular Endothelial Growth Factor A -- genetics
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.